Q1 2024 revenue of $8.0 million, representing 50% growth over Q1 2023 and the 13th straight quarter of sequential product sales growth Acquired PKU GOLIKE®, launched Nitisinone, and submitted a...
DEER PARK, Ill., May 01, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare...
- Company anticipates 10-month review for potential approval in Q1 2025 -- Eton expects ET-400 and Alkindi Sprinkle® to achieve potential combined peak sales of more than $50 million annually --...
Relief Enters into Exclusive License Agreement with Eton for PKU GOLIKE
PKU GOLIKE® is a commercial ultra-rare disease medical formula complementary to Eton's existing metabolic franchise and specialty call pointTransaction is expected to be accretive to 2024...
Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
Eton to Report Fourth Quarter and Full Year 2023 Financial Results
DEER PARK, Ill., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals (Eton or the Company) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing...
Eton Announces Commercial Availability of Nitisinone Capsules